New radiation approach before surgery for rare adrenal cancer
NCT ID NCT06487481
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times
Summary
This early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiation for 2-3 weeks, then have surgery 4 weeks later, and be followed for up to 10 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- radiation therapy
- What this could lead to
- If it works, this could make surgery more effective for recurrent ACC and improve how long people live without the cancer coming back.
- What could go wrong
- This is a very early phase 1 trial with only 32 people, so it is not yet clear if the radiation helps. There are risks from radiation and surgery, and the cancer may still return.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA (ACC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.